291 related articles for article (PubMed ID: 11407654)
1. Impairment of GH responsiveness to GH-releasing hexapeptide (GHRP-6) in Prader-Willi syndrome.
Grugni G; Guzzaloni G; Morabito F
J Endocrinol Invest; 2001 May; 24(5):340-8. PubMed ID: 11407654
[TBL] [Abstract][Full Text] [Related]
2. Reduced growth hormone (GH) responsiveness to combined GH-releasing hormone and pyridostigmine administration in the Prader-Willi syndrome.
Grugni G; Guzzaloni G; Moro D; Bettio D; De Medici C; Morabito F
Clin Endocrinol (Oxf); 1998 Jun; 48(6):769-75. PubMed ID: 9713567
[TBL] [Abstract][Full Text] [Related]
3. GH/IGF-I axis in Prader-Willi syndrome: evaluation of IGF-I levels and of the somatotroph responsiveness to various provocative stimuli. Genetic Obesity Study Group of Italian Society of Pediatric Endocrinology and Diabetology.
Corrias A; Bellone J; Beccaria L; Bosio L; Trifirò G; Livieri C; Ragusa L; Salvatoni A; Andreo M; Ciampalini P; Tonini G; Crinò A
J Endocrinol Invest; 2000 Feb; 23(2):84-9. PubMed ID: 10800760
[TBL] [Abstract][Full Text] [Related]
4. Impairment of GH responsiveness to combined GH-releasing hormone and arginine administration in adult patients with Prader-Willi syndrome.
Grugni G; Marzullo P; Ragusa L; Sartorio A; Trifirò G; Liuzzi A; Crinò A;
Clin Endocrinol (Oxf); 2006 Oct; 65(4):492-9. PubMed ID: 16984242
[TBL] [Abstract][Full Text] [Related]
5. The growth hormone response to hexarelin in patients with Prader-Willi syndrome.
Cappa M; Raguso G; Palmiotto T; Faedda A; Gurreri F; Neri G; Deghenghi R; Loche S
J Endocrinol Invest; 1998 Sep; 21(8):501-5. PubMed ID: 9801990
[TBL] [Abstract][Full Text] [Related]
6. Growth hormone secretory pattern in non-obese children and adolescents with Prader-Willi syndrome.
Grugni G; Crinò A; Pagani S; Meazza C; Buzi F; De Toni T; Gargantini L; Pilotta A; Pozzan GB; Radetti G; Ragusa L; Salvatoni A; Sartorio A; Bozzola M;
J Pediatr Endocrinol Metab; 2011; 24(7-8):477-81. PubMed ID: 21932585
[TBL] [Abstract][Full Text] [Related]
7. Body fat excess and stimulated growth hormone levels in adult patients with Prader-Willi syndrome.
Grugni G; Crinò A; Bertocco P; Marzullo P
Am J Med Genet A; 2009 Feb; 149A(4):726-31. PubMed ID: 19267411
[TBL] [Abstract][Full Text] [Related]
8. The GHRH + arginine stimulated pituitary GH secretion in children and adults with Prader-Willi syndrome shows age- and BMI-dependent and genotype-related differences.
Marostica E; Grugni G; De Nicolao G; Marazzi N; Crinò A; Cappa M; Sartorio A
Growth Horm IGF Res; 2013 Dec; 23(6):261-6. PubMed ID: 24090687
[TBL] [Abstract][Full Text] [Related]
9. Growth hormone (GH) response to GH-releasing peptide-6 and GH-releasing hormone in normal-weight and overweight patients with non-insulin-dependent diabetes mellitus.
Micić D; Macut D; Popović V; Kendereski A; Sumarac-Dumanović M; Zorić S; Dieguez C; Casanueva FF
Metabolism; 1999 Apr; 48(4):525-30. PubMed ID: 10206449
[TBL] [Abstract][Full Text] [Related]
10. Comparison between insulin tolerance test, growth hormone (GH)-releasing hormone (GHRH), GHRH plus acipimox and GHRH plus GH-releasing peptide-6 for the diagnosis of adult GH deficiency in normal subjects, obese and hypopituitary patients.
Cordido F; Alvarez-Castro P; Isidro ML; Casanueva FF; Dieguez C
Eur J Endocrinol; 2003 Aug; 149(2):117-22. PubMed ID: 12887288
[TBL] [Abstract][Full Text] [Related]
11. The GHRH/GHRP-6 test for the diagnosis of GH deficiency in elderly or severely obese men.
Haijma SV; van Dam PS; de Vries WR; Maitimu-Smeele I; Dieguez C; Casanueva FF; Koppeschaar HP
Eur J Endocrinol; 2005 Apr; 152(4):575-80. PubMed ID: 15817913
[TBL] [Abstract][Full Text] [Related]
12. Unaltered ratio of circulating levels of growth hormone/GH isoforms in adults with Prader-Willi syndrome after GHRH plus arginine administration.
Rigamonti AE; Grugni G; Marazzi N; Bini S; Bidlingmaier M; Sartorio A
Growth Horm IGF Res; 2015 Aug; 25(4):168-73. PubMed ID: 26059749
[TBL] [Abstract][Full Text] [Related]
13. Growth hormone (GH) response to GH-releasing peptide-6 in type 1 diabetic patients with exaggerated GH-releasing hormone-stimulated GH secretion.
Catalina PF; Mallo F; Andrade MA; García-Mayor RV; Diéguez C
J Clin Endocrinol Metab; 1998 Oct; 83(10):3663-7. PubMed ID: 9768681
[TBL] [Abstract][Full Text] [Related]
14. The impact of cranial irradiation on GH responsiveness to GHRH plus GH-releasing peptide-6.
Popovic V; Pekic S; Golubicic I; Doknic M; Dieguez C; Casanueva FF
J Clin Endocrinol Metab; 2002 May; 87(5):2095-9. PubMed ID: 11994347
[TBL] [Abstract][Full Text] [Related]
15. GHRH plus arginine and arginine administration evokes the same ratio of GH isoforms levels in young patients with Prader-Willi syndrome.
Rigamonti AE; Crinò A; Bocchini S; Convertino A; Bidlingmaier M; Haenelt M; Tamini S; Cella SG; Grugni G; Sartorio A
Growth Horm IGF Res; 2018 Apr; 39():13-18. PubMed ID: 29217318
[TBL] [Abstract][Full Text] [Related]
16. Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity.
Cordido F; Peñalva A; Dieguez C; Casanueva FF
J Clin Endocrinol Metab; 1993 Apr; 76(4):819-23. PubMed ID: 8473389
[TBL] [Abstract][Full Text] [Related]
17. Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression.
Cordido F; Peino R; Peñalva A; Alvarez CV; Casanueva FF; Dieguez C
J Clin Endocrinol Metab; 1996 Mar; 81(3):914-8. PubMed ID: 8772550
[TBL] [Abstract][Full Text] [Related]
18. Acute dexamethasone administration enhances GH responsiveness to GH releasing peptide-6 (GHRP-6) in man.
Pinto AC; Finamor FE; Lengyel AM
Clin Endocrinol (Oxf); 1999 Oct; 51(4):409-14. PubMed ID: 10583306
[TBL] [Abstract][Full Text] [Related]
19. Deconvolution-based assessment of pituitary GH secretion stimulated with GHRH+arginine in Prader-Willi adults and obese controls.
Grugni G; Marostica E; Crinò A; Marzullo P; De Nicolao G; Sartorio A
Clin Endocrinol (Oxf); 2013 Aug; 79(2):224-31. PubMed ID: 23301953
[TBL] [Abstract][Full Text] [Related]
20. Acipimox-mediated plasma free fatty acid depression per se stimulates growth hormone (GH) secretion in normal subjects and potentiates the response to other GH-releasing stimuli.
Peino R; Cordido F; Peñalva A; Alvarez CV; Dieguez C; Casanueva FF
J Clin Endocrinol Metab; 1996 Mar; 81(3):909-13. PubMed ID: 8772549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
